ORM-1153: Anti-CD123 Antibody-Enabled GSPT1 Degrader for Hematologic Malignancies

( ASH 2025 )

PROTAb Platform: An Innovative Universal Linker for DACs with Cereblon-Based Degraders

( ADC Linker & Conjugation Summit 2024 )

ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
( ASH 2022 | AACR 2023 )

ORM-5029: A First-in-Class, Tumor-Targeted, Targeted Protein Degradation Therapy for HER2-Positive Breast Cancer
( AACR 2022 )

Development of RNAscope Multiplex-Based Assay for Exploratory Pharmacodynamic Biomarkers Assessment in Breast Cancer Patients from Phase I Clinical Trial Of ORM-5029, a Potent GSPT1 Degrader
( AACR 2023 )

A Phase 1, First-in-human, Open Label, Escalation and Expansion Study of ORM-5029, A Highly Potent GSPT1 Degrader Targeting HER2, in Patients with HER2-expressing Advanced Solid Tumors (NCT05511844)
( ASCO 2023 )

ORM-5029: Discovery of an antibody drug conjugate with first-in-class molecular glue degrader warhead for treatment of HER2-positive breast cancer
( ACS 2023 )